While, previously, patients with severe OSA would likely require CPAP therapy for the remainder of their lives, especially as OSA tends to worsen with age and weight increase, these obesity-targeting medications offer the potential for some patients to become less dependent on CPAP or be managed using lower, more tolerable pressures. Indeed, patients on tirzepatide had about a 50% reduction in the apnea-hypopnea index and significant improvements in hypoxemia
Consequently, Mounjaro stands out with its dual mechanism that may offer additional benefits for people managing type 2 diabetes, setting it apart from its counterparts in the GLP-1 category
Busy schedules, stress, and poor nutrition can all take a toll on your energy and overall wellness
Related links Rights and permissions Springer Nature or its licensor (e.g
My team and I set out to test whether GLP-1 drugs medications like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), originally developed for diabetes and then approved for obesity could do what no existing addiction treatment does: curb craving itself
